Antiverse is building a world-first computational antibody drug discovery platform. We combine in-house lab expertise with state of the art machine learning to predict antibody-antigen binding and provide antibody drug candidates in weeks.
Location: United Kingdom
Employees: 1-10
Total raised: $18.84M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | Nlsventure... | nlsventure... |
| - | Cambridge ... | cambridgea... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 03.03.2026 | Series A | $9.3M | Soulmates ... |
| 16.10.2024 | Seed | $4.6M | - |
| 02.03.2023 | - | $3M | Tensor Ven... |
| 15.03.2021 | - | $1.95M | - |
Mentions in press and media 19
| Date | Title | Description |
| 03.03.2026 | Antiverse Raises $9.3M in Series A Funding | Antiverse, a Cardiff, Wales, UK-based AI-driven techbio company, raised $9.3M in Series A funding. The round was led by Soulmates Ventures with participation from Innovation Investment Capital, DOMiNO Ventures and existing investors DBW, Ka... |
| 03.03.2026 | Antiverse secures $9.3M Series A for AI antibody platform | UK-based Antiverse, a biotech company developing AI-designed therapeutic antibodies for hard-to-target disease targets, has closed a $9.3 million Series A round led by Soulmates Ventures, with participation from Innovation Investment Capita... |
| 17.10.2024 | Antiverse: Pioneering the Future of Antibody Design with AI | In the realm of biotechnology, innovation is the lifeblood that fuels progress. Antiverse, a Cardiff-based techbio company, is harnessing the power of generative AI to revolutionize antibody design. Recently, the company secured €4.2 millio... |
| 16.10.2024 | Antiverse raises £3.5M ($4.6M) to advance generative AI antibody design platform | Increases total equity financing raised to £7.2M ($10.1M) New facilities in Boston and Prague will provide increased capacity to deliver pipeline of pharma and biotech projects Funding to progress internal assets targeting multiple GPCRs an... |
| 15.10.2024 | Cardiff-based Antiverse secures €4.2 million to advance generative AI antibody design | Antiverse, a techbio company designing antibodies for challenging targets, has announced the successful closure of €4.2 million seed funding round. This latest investment brings the company’s total equity financing to €8.6 million, marking ... |
| 15.10.2024 | Antiverse Raises £3.5M in Seed Funding | Antiverse, a Cardiff, Wales, UK-based techbio company designing antibodies for challenging targets, raised £3.5M in Seed funding. The round, which brought the total amount to £7.2M, was led by i&i Biotech Fund I (i&i Bio) and Kadmos... |
| 16.10.2023 | Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics | Cardiff, UK and Massachusetts, US - Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, and GlobalBio, Inc. (GlobalBio), an antibody engineering company developing methods to engin... |
| 02.03.2023 | Czech Tensor Ventures backs Antiverse as part of $3M investment round | Czech Tensor Ventures backs Antiverse as part of $3M investment round 02 March, 2023, 17:14 Rostyslav Sobachynskyi --> --> --> -->--> --> --> --> --> --> --> --> --> Prague-based deeptech fund Tenso... |
| 02.03.2023 | Antiverse Raises $3M in Funding | Antiverse, a Cardiff, UK-based biotechnology company developing a computational antibody drug discovery platform, raised $3M in funding. Backers included InnoSpark, AngelHub, Kadmos Capital and Tomorrow Scale, as well as existing investors,... |
| 01.03.2023 | Cardiff-based Antiverse raises €2.8M for its computational antibody drug discovery platform | Cardiff-based Antiverse, a biotechnology company developing a computational antibody drug discovery platform, announced on Wednesday that it has raised £2.5M (approximately €2.82M) in a fresh round of funding. The funding came from InnoSpar... |
Show more